8:00 am Coffee & Networking

8:15 am Chair’s Opening Remarks

• Jesse Cotari Co-Founder & Scientific Advisor, ImmuneBridge

Enhancing Therapeutic Precision to Identify Critical Biomarkers, Establish Rigorous Specificity Standards, & Improve the Accuracy & Effectiveness Of Cell Therapy Interventions

8:30 am Fireside Chat: Mapping the Crucial Role of Donor Selection in the Future of Biotech & Pharma to Streamline Commercialization

• Ben Beneski Vice President, Product Development and Manufacturing, Allogene Therapeutics
• Jesse Cotari Co-Founder & Scientific Advisor, ImmuneBridge
• Armin Rath Chief Operating Officer, Cytovia Therapeutics
• Speaker To Be Confirmed , Comprehensive Cell Solutions

9:15 am Navigating the Complexities in Biomarker Discovery & Setting Standards for Biomarker Specificity

• Lakshmi M Boppana Director - CGT IT Systems, Vertex Pharmaceuticals

10:15 am Morning Refreshments & Networking

Integrating Robust Donor Selection Methods into Manufacturing, Scale-Up Operations & Downstream Drug Development to Maximize Therapeutic Effects

11:15 am Tentative – Ensuring Donor Product Compatibility & Consistency in Downstream Drug Development to Maximize Therapeutic Efficacy

• Akshata Ijantkar Analytical Lead for BMS Cell Therapy Products, Bristol Myers Squibb

11:45 am Pre-Clinical Ex Vivo Efficacy for Cell & Gene Therapies – A Donor Case Study

• Raluca Dumitru Scientific Sales Advisor, Charles River Laboratories

11:55 am Enhancing Donor Selection in Autologous Cell Therapy: Overcoming Challenges in Process Optimization & Scaling Up with Consistency & Safety

• Nidheesh Dadheech Senior Cell Therapy Lead, University of Alberta

Critical Considerations in Donor Selection: Balancing Safety, Risk-Benefit Profiles, & Selecting Optimal Starting Materials between Donor-Derived & iPSC Therapies

12:25 pm Comparing Donor-Derived & iPSC-Derived Therapies for Market Entry & Long-Term Viability

12:55 pm Lunch & Networking

2:00 pm Audience Led Discussion: Balancing Safety & Benefit-Risk in Donor Selection by Evaluating Metabolic Fitness, Memory & Cytokine Risks

• Jesse Cotari Co-Founder & Scientific Advisor, ImmuneBridge

2:30 pm Advancing Cryopreservation Strategies for Donor Products by Enhancing Viability, Ensuring Long-Term Stability, & Maximizing Therapeutic Efficacy

• Tracey Turner Principal Scientist, Bristol Myers Squibb

3:00 pm Roundtable Discussion: Evaluating Starting Materials for Donor Cells with a Focus on Quality, Reliability, & Logistics Considerations

• Stephen Chen Chief Technical Officer, Tevogen Bio

3:30 pm Chair’s Closing Remarks

• Jesse Cotari Co-Founder & Scientific Advisor, ImmuneBridge

3:45 pm Close of Summit